tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Takeda’s Narcolepsy Drug Study Abstract Accidentally Published
Company AnnouncementsTakeda’s Narcolepsy Drug Study Abstract Accidentally Published
15d ago
Takeda Pharmaceutical Reports Q1 2025 Earnings with Profit Growth
PremiumCompany Announcements
Takeda Pharmaceutical Reports Q1 2025 Earnings with Profit Growth
15d ago
Takeda reports Q1 core EPS 151 yen vs. 176 yen last year
PremiumThe Fly
Takeda reports Q1 core EPS 151 yen vs. 176 yen last year
16d ago
TAK
Takeda backs FY25 core EPS view 485 yen
PremiumThe Fly
Takeda backs FY25 core EPS view 485 yen
16d ago
TAK
Takeda Pharmaceutical Reports Mixed Financial Results for Q2 2025
PremiumCompany Announcements
Takeda Pharmaceutical Reports Mixed Financial Results for Q2 2025
16d ago
Alkermes selling off on limited data disclosure, says BofA
PremiumThe FlyAlkermes selling off on limited data disclosure, says BofA
25d ago
TAK
ALKS
Takeda receives FDA clearance for HyHub, HyHub Duo
Premium
The Fly
Takeda receives FDA clearance for HyHub, HyHub Duo
25d ago
TAK
Avidity, Phathom mentioned as potential takeout targets at Needham
Premium
The Fly
Avidity, Phathom mentioned as potential takeout targets at Needham
29d ago
BMY
NVO
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
PremiumThe Fly
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
29d ago
TAK
KROS
Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton
PremiumRatings
Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton
1M ago
TAK
Morning Movers: Sonnet BioTherapeutics skyrockets after $888M combination
PremiumThe Fly
Morning Movers: Sonnet BioTherapeutics skyrockets after $888M combination
1M ago
AZN
TAK
Takeda announces oveporexton studies met all primary, secondary endpoints
PremiumThe Fly
Takeda announces oveporexton studies met all primary, secondary endpoints
1M ago
TAK
Takeda’s Oveporexton Shows Promise in Phase 3 Narcolepsy Studies
PremiumCompany AnnouncementsTakeda’s Oveporexton Shows Promise in Phase 3 Narcolepsy Studies
1M ago
Takeda Completes Treasury Share Disposal with Minor Adjustments
Premium
Company Announcements
Takeda Completes Treasury Share Disposal with Minor Adjustments
1M ago
Takeda announces FDA approval of Gammagard Liquid ERC
Premium
The Fly
Takeda announces FDA approval of Gammagard Liquid ERC
2M ago
TAK
Takeda Announces New Director Assignments, Emphasizing Strong Governance
PremiumCompany Announcements
Takeda Announces New Director Assignments, Emphasizing Strong Governance
2M ago
Takeda Announces Disposal of Treasury Shares for Global Employee Incentive Plan
PremiumCompany Announcements
Takeda Announces Disposal of Treasury Shares for Global Employee Incentive Plan
2M ago
Takeda reports EC approves Adcetris combination for Hodgkin lymphoma
PremiumThe Fly
Takeda reports EC approves Adcetris combination for Hodgkin lymphoma
2M ago
TAK
Positive Outlook for Takeda Pharmaceutical Co: Buy Rating Supported by Promising Phase 3 Data and Projected Sales for Rusfertide
PremiumRatings
Positive Outlook for Takeda Pharmaceutical Co: Buy Rating Supported by Promising Phase 3 Data and Projected Sales for Rusfertide
2M ago
TAK
Takeda Announces New Shelf Registration for LTIP Support
PremiumCompany AnnouncementsTakeda Announces New Shelf Registration for LTIP Support
2M ago
Takeda and Protagonist Reveal Positive Phase 3 VERIFY Study Results
Premium
Company Announcements
Takeda and Protagonist Reveal Positive Phase 3 VERIFY Study Results
2M ago
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
Premium
The Fly
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
2M ago
TAK
PTGX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >